image credit: Pexels

Lonza Acquires Roche’s US Commercial Biologics Manufacturing Site for $1.2 Billion

March 25, 2024

Lonza announced on March 20, 2024 that is has signed an agreement to acquire from Roche its Vacaville, Calif., site, a large-scale biologics manufacturing site, for $1.2 billion. Beyond the acquisition, Lonza plans to invest approximately CHF 500 million (US$557 million) to upgrade the facility and enhance capabilities for serving the next generation of mammalian biologics.

The deal is expected to close in the second half of 2024, subject to customary closing conditions. The Vacaville site will be integrated into Lonza’s Biologics division upon closing and will be included in Lonza’s network of existing mammalian manufacturing sites in Visp, Switzerland; Slough, United Kingdom; Tuas, Singapore; Portsmouth, NH; and Porriño, Spain.

Read More on Biopharm International